Your browser doesn't support javascript.
loading
New therapeutic protocol for improvement of endometrial receptivity (PRIMER) for patients with recurrent implantation failure (RIF) - A pilot study.
Dieamant, Felipe; Vagnini, Laura D; Petersen, Claudia G; Mauri, Ana L; Renzi, Adriana; Petersen, Bruna; Mattila, Mariana C; Nicoletti, Andreia; Oliveira, Joao Batista A; Baruffi, Ricardo; Franco, Jose G.
Afiliación
  • Dieamant F; Center for Human Reproduction Prof Franco Jr. Ribeirão Preto, Brazil.
  • Vagnini LD; Paulista Center for Diagnosis Research and Training. Ribeirão Preto, Brazil.
  • Petersen CG; Paulista Center for Diagnosis Research and Training. Ribeirão Preto, Brazil.
  • Mauri AL; Center for Human Reproduction Prof Franco Jr. Ribeirão Preto, Brazil.
  • Renzi A; Paulista Center for Diagnosis Research and Training. Ribeirão Preto, Brazil.
  • Petersen B; Center for Human Reproduction Prof Franco Jr. Ribeirão Preto, Brazil.
  • Mattila MC; Paulista Center for Diagnosis Research and Training. Ribeirão Preto, Brazil.
  • Nicoletti A; Paulista Center for Diagnosis Research and Training. Ribeirão Preto, Brazil.
  • Oliveira JBA; Center for Human Reproduction Prof Franco Jr. Ribeirão Preto, Brazil.
  • Baruffi R; Paulista Center for Diagnosis Research and Training. Ribeirão Preto, Brazil.
  • Franco JG; Center for Human Reproduction Prof Franco Jr. Ribeirão Preto, Brazil.
JBRA Assist Reprod ; 23(3): 250-254, 2019 08 22.
Article en En | MEDLINE | ID: mdl-31091064
OBJECTIVE: To evaluate whether or not one should use a new Protocol for Endometrial Receptivity Improvement (PRIMER) based on platelet-rich plasma (PRP) and granulocyte colony-stimulation factor (G-CSF) to enhance ongoing pregnancy rates in patients with recurrent implantation failure (RIF). METHODS: Women undergoing IVF/ICSI were prospectively divided into two groups: - PRIMER/RIF group (n:33): patients with RIF (defined as ≥2embryo transfers (ETs) and at least 5 morphologically good embryos transferred) in which intrauterine PRP injection and subcutaneous G-CSF-injection were performed. - Control group (n:33): patients in their first IVF/ICSI attempt/cycle (without PRP or G-CSF injection). The PRP was prepared using autologous fresh-whole blood processed to increase platelet-concentration in 2 to 4 fold. All patients undergoing the PRP-treatment received 0.7ml of it through intrauterine-injection 48 hours before the ET. G-CSF (300mg/0.5ml) started simultaneously to PRP and was administered subcutaneously every week. RESULTS: Regarding implantation, clinical pregnancy and miscarriage rates, we found no statistically significant difference (18.2% versus 17.6%, p=0.90; 36.4% versus 30.3%, p=0.61 and 25.0% versus 9.0%, p=0.43, respectively). The use of PRIMER enabled RIF patients (previous ET µ: 4.0±1.5) to reach similar ongoing pregnancy and live birth rates like those patients who had their first IVF/ICSI cycle attempt (27.3% versus 27.3%, p=0.99). CONCLUSIONS: Our results showed, for the first time, evidence that this therapeutic protocol (PRIMER) could be used as a feasible treatment based on biological rationale for patients with RIF, considering its promising outcomes, it is a simple procedure and not associated with patient complications.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Implantación del Embrión / Aborto Habitual / Factor Estimulante de Colonias de Granulocitos / Transfusión de Componentes Sanguíneos / Terapias en Investigación / Plasma Rico en Plaquetas Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Female / Humans / Male / Middle aged / Newborn / Pregnancy Idioma: En Revista: JBRA Assist Reprod Año: 2019 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Brasil

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Implantación del Embrión / Aborto Habitual / Factor Estimulante de Colonias de Granulocitos / Transfusión de Componentes Sanguíneos / Terapias en Investigación / Plasma Rico en Plaquetas Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Female / Humans / Male / Middle aged / Newborn / Pregnancy Idioma: En Revista: JBRA Assist Reprod Año: 2019 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Brasil